Health ProductsDear Healthcare Professional Letter

Magnesium Sulfate Injection USP 50%, 50 mL Vial - Recall Due to Potential Presence of Glass Particles - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Issue: Contamination
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Pharmaceutical Partners of Canada Inc. (PPC). Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on Magnesium Sulfate Injection, USP

May 17, 2013

Dear Health Care Professional,

Subject: Recall of Magnesium Sulfate Injection, USP 50%, 50 mL vial, Lot 6103881, expiry date October 2014, due to potential for glass particles

Pharmaceutical Partners of Canada Inc. (PPC), in consultation with Health Canada, has initiated a voluntary recall of Magnesium Sulfate Injection, USP Lot 6103881 (DIN 02139499) due to potential for glass particles. Recent inspection carried out on retention samples by the manufacturer revealed that the product with above mentioned lot number may contain glass particles. The affected lot has been distributed on the Canadian market from June 12, 2012 to July 30, 2012.

Magnesium Sulfate Injection, USP is indicated as a CNS depressant, primarily in preeclampsia and eclampsia of pregnancy and as an electrolyte replenisher for hypomagnesemia and magnesium deficiency to maintain normal neuromuscular irritability. 

  • There is a potential for glass particles to be present in Magnesium Sulfate Injection USP. In the event where glass particles are injected into a patient, there is the potential for patient injury
  • Examine your stock immediately, including product being home administered. Vials of the affected lot should not be used and be returned to Pharmaceutical Partners of Canada, Inc.

Injected glass particles may result in phlebitis, acute inflammation, allergic reaction, and/or embolization to other organs in the body.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or other serious or unexpected adverse reactions in patients receiving Magnesium Sulfate Injection Lot 6103881 should be reported to Pharmaceutical Partners of Canada Inc. or Health Canada.

Pharmaceutical Partners of Canada Inc.
45 Vogell Road
Richmond Hill, ON
L4B 3P6

You can report any suspected adverse reactions associated with the use of health products, to Health Canada by:

  • Calling toll-free at 1-866-234-2345, or:
  • Visiting MedEffect Canada’s web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.

For other health product inquiries related to this communication, contact Health Canada at:
Health Product and Food Branch Inspectorate
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Tel: 1-800-267-9676
Fax: 613-946-5636

Sincerely,

original signed by

Jim Walker
Vice President Scientific Affairs

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime